We formed in 2025 and the group reviews requests and correspondence to ISPAD in relation to screening, monitoring and disease modifying agents in the early-stage T1D space.
We have representation from USA, Europe, UK, Australia and India. The main work has been around the IDF brief and policy release in conjunction with ISPAD in February 2026:
Detect early; Act early: improving diagnosis of T1D.